NDL is a shell with a great potential . Beijing Tide intends to...

NDL is a shell with a great potential .


Beijing Tide intends to conduct a proof of principle Phase II clinical trial at its sole discretion with respect to financing and clinical design. Importantly, Beijing Tide will maintain the current patent portfolio world-wide while it continues development in China. This would mean that upon clinical success or commercialisation in China, Sosei may choose to have certain territories outside China re- assigned to Sosei.
The Sosei and Beijing Tide Assignment Agreement ensures the NSL-043 program can now potentially move forward into Phase II trial/s.
NeuroDiscovery is pleased it continues to have a potentially significant commercial interest in the NSL-043 program.

https://trading.nab.com.au/ComNews/20120813/01322546.pdf